Thus, due to the ability to target cyclin D, combined with the likely maintenance of the Rb inhibition of E2F, cell cycle progression from G1 to S phase is an ideal therapeutic target in HR-positive breast cancers [66,67,68]. Here, RB1 is linked to breast carcinoma.